Dr.LipidDallas said:The line between titrate-through and stop is not severity, it is trajectory and what else is present.
I dislike how confidently this board tells people to push through. Incidence figures around 20 to 25% at the higher doses are class-typical, but the trials also had a discontinuation column, and "manageable with protocols" is not the same as manageable for everyone.
Adding the numbers, since they settle part of this. One habit that pays for itself: post the method alongside the number. A figure without its method cannot be checked, and an unchecked figure is how this community accumulates folklore.
Dr.KarenChen said:I dislike how confidently this board tells people to push through.
There is a second half to this that has not been said yet. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemOne thing that is still open after BiostatsBrad’s answer:
Whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out?
Closing the loop on my own question.
Update. It was not the dose, it was that I had stopped drinking anything because drinking made me feel full. Fixing that fixed most of it.